Right ventricular failure

Vol. 14, N° 32 - 12 Dec 2016

Dr. Bassem Sobhi Ibrahim

Cardiologists have become 'LV centric' though circulation is a closed system and the RV plays an
integral part in it. A complex interventricular dependence between both ventricles is present. The RV
fails when there is pressure or volume overload or myocardial disease such as RV infarction or
cardiomyopathy. However, the commonest cause of RV failure is pulmonary hypertension.
Epidemiologically, the most frequent pathology for pulmonary hypertension development is LV
failure. Diagnosis of RV failure is a clinical exercise. ECG and markers such as lactate and BNP are
helpful. Echo is very important in the diagnosis to exclude extrinsic causes and to quantify, in
particular, PASP, IVC diameter and collapsibility index and TAPSE. CT and cardiac MRI have been
useful to elucidate the underlying pathology.
Topic(s):
Heart Failure

Introduction

Many a time the right ventricle (RV) is regarded as the 'younger brother' of the left ventricle (LV)
and is treated as a less important member of the contractile apparatus. This view stems from the
concept that the RV functions rather as a passive conduit and its importance is not great as it pumps
blood to only one organ, the lungs. However, the circulatory system is a closed one, and both
ventricles are interdependent working together in an orchestrated complex pattern in health and
disease. The failure of one ventricle deleteriously affects the performance of the other. This review
will deal with the causes of right ventricular failure and its diagnosis, leaving the management to a
second part of this series.

Background

Anatomically the RV is triangular in side section and crescent-like in cross-section. It is made up of

superficial, circular and deeper longitudinal fibres. The superficial fibres encircle the heart and are
continuous with the subepicardial fibres of the LV. The deep longitudinal fibres run from the apex to
the base of the heart. The RV contracts in three ways: the inward motion of the RV free wall; via
shortening of longitudinal fibres pulling the apex towards the base of the heart; and through traction
by LV contraction. The contraction of longitudinal fibres contributes most to the systolic
performance of the RV, whilst the LV traction component contributes about 20-40% of RV cardiac
output.
The RV ejects the same stroke volume as the LV, but against a much lower resistance of the
pulmonary vasculature. This results in an RV stroke work which is almost one-fourth that of the LV,
hence the thinner RV wall. Because of the low resistance presented by the pulmonary circulation, the
RV continues to eject through the early phase of systole. As such, there is no isovolumic relaxation
phase on the right side.
There is important ventricular interdependence between the RV and the LV via the sharing by both
ventricles of the interventricular septum (IVS), the insertion of anterior and posterior ends of the RV
free wall into the IVS, the encircling fibres and the pericardium. Acute dilatation of the RV, for
example, in RV infarction or significant pulmonary embolism shifts the septum to the left. This shift
raise impairs LV diastolic filling, as well as its contractility. The constraining effect of the pericardial
sac comes into play in diastole when a dilated ventricle restricts the filling of the other.
The RV cannot handle a pressure overload in the same way as a volume overload which it can
withstand for years. However, to maintain cardiac output in the face of an acute rise of pulmonary
pressure – e.g. in the context of large pulmonary embolus – the RV augments its force of contraction.
Failure to adapt acutely results in rapid RV dilatation and dysfunction which is clinically manifest as
hypotension and cardiogenic shock. On the other hand, when pulmonary arterial pressure (PAP) rises
more gradually, the RV dilates using Starling’s law to preserve flow output. Usually, RV function is
maintained until late stages of the disease. Eventually, the RV fails, becomes more spherical,
tricuspid regurgitation ensues causing more right heart failure and a spiral process develops ending in
venous system congestion.
It is important to elaborate on right heart failure (RHF) in the presence of left-sided failure as this is
the most common scenario. Some of the mechanisms as to why RHF follows left-sided heart failure
(HF) are: 1) they may both be affected by the same pathology whether it is ischaemia, inherited
cardiomyopathy or myocarditis; 2) development of pulmonary hypertension in left ventricular failure
(LVF) increases the afterload against which the RV has to pump; 3) severe LVF may result in
decreased coronary perfusion for the right ventricle; and 4) LV dilatation can impair RV diastolic
function by increasing pericardial constraint. Nowadays, with the increasing use of ACE inhibitors
and beta-blockers, patients with LVF more frequently survive to develop pulmonary hypertension
and finally succumb with right ventricular failure. This is the reason why RV failure is considered
'the common final pathway'. [1] Time and again, it has been shown to be the most important indicator
of poor prognosis in heart failure.

Prevalence
Right heart failure as the primary presentation of acute decompensated HF and cause of
hospitalisation accounted for 2.2% of HF admissions in the CHARITEM registry; [2] however, it
was present as secondary to acute LV failure in more than one-fifth of the cases.
In our Egyptian Heart Failure-LT registry, 4.5% of patients with acute heart failure presented with
RHF as opposed to 3% in other ESC regions. [3] This could be attributed to the even higher
incidence of rheumatic heart disease. In support of this, Hassanein et al. reported that the incidence of
valvular heart disease was more than double than in the other ESC regions (17.5% of our cohort
versus 8%) in the same registry. [3] Rheumatic fever affects the mitral valve mainly in the form of
stenosis, but also mitral regurgitation or a combination of both. Neglected mitral valve disease results
in pulmonary hypertension, severe functional tricuspid regurgitation and right-sided heart failure. In
addition, rheumatic heart disease not infrequently causes organic tricuspid valve disease (stenosis,
regurgitation or a combination of both). Decades ago, infection by S. Mansoni caused pulmonary
hypertension in Upper Egypt, but the eradication programmes for schistosomiasis have resulted in
this problem now being a rare occurrence. It is still endemic in sub-Saharan Africa.

Causes of right heart failure

The causes of RHF can be divided broadly into three categories: secondary to pulmonary
hypertension; RV and tricuspid valve pathology; and diseases of the pericardium.
Pulmonary hypertension (PH) is the most common cause of RHF (Table 1). The commonest cause of
pulmonary hypertension is left-sided heart failure. LVF, whether due to systolic HF or HF with
preserved LV systolic function or severe mitral valve disease, results in PH and, if left untreated,
leads to RHF. This is termed PH type 2, according to the WHO classification and is a post-capillary
PH as it is associated with high wedge pressure [4].

Table 1. Classification of pulmonary hypertension

1. Pulmonary Arterial Hypertension (PAH)

1.1. Idiopathic (IPAH)
1.2. Heritable
1.3. Drugs and toxins
1.4. Associated with:
1.4.1. Connective tissue disease
1.4.2. HIV infection
1.4.3. Portal hypertension
1.4.4. Congenital systemic-to-pulmonary shunts
1.4.5. Schistosomiasis
1’. Pulmonary veno-occlusive disease
1” Persistent pulmonary hypertension of the newborn
2. Pulmonary Hypertension Secondary to Left Heart Disease
2.1. Left ventricular systolic dysfunction
2.2. Left ventricular diastolic dysfunction
2.3. Left-sided valvular heart disease
3. Pulmonary Hypertension Associated with Lung Diseases and/or Hypoxaemia
3.1. Chronic obstructive pulmonary disease
 Table 1. Classification of pulmonary hypertension

3.2. Interstitial lung disease

3.3. Sleep-disordered breathing
3.4. Alveolar hypoventilation disorders
3.5. Chronic exposure to high altitude
3.6. Developmental abnormalities
4. Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
5. Miscellaneous
5.1. Haematological
Chronic haemolytic anaemias, sickle cell, thalassaemia
Myeloproliferative disorders
Post-splenectomy
5.2. Systemic disorders
e.g., sarcoidosis
5.3. Metabolic disorders
a. thyroid disorders
b. glycogen storage diseases
c. Gaucher’s disease
5.4. Others
e.g., chronic renal failure, fibrosing mediastinitis

PH types 1, 3, 4 and most of 5 in the WHO classification are pre-capillary; all are characterised by
low or normal wedge pressure. The second most common cause of PH is secondary to lung disease.
The commonest lung diseases are obstructive airway disease followed by lung fibrosis. Another
important cause which is frequently overlooked is obstructive sleep apnoea (OSA). PH is present in
17-53% of individuals with OSA [5]. Lung diseases cause pulmonary hypertension via hypoxia
which causes polycythaemia, vasoconstriction and vascular remodelling, in addition to damage of
lung parenchyma with loss of vascular bed.
A particular type of PH results from acute pulmonary embolism, and can result in acute right heart
failure as the RV fails to maintain blood flow past an obstructing large embolus. Recurrent showers
of smaller pulmonary emboli can end in chronic thromboembolic pulmonary hypertension (CTEPH).
Here emboli do not completely resolve, but they partially recanalise and are endothelialised, resulting
in pulmonary artery obstruction.
All congenital heart diseases with increased pulmonary blood flow, mainly left-to-right shunts, can
lead to PH. The development of PH depends on the duration of exposure and its magnitude, i.e.,
ventricular septal defect and patent ductus arteriosus (post-tricuspid defects) patients tend to develop
PH earlier than atrial septal defect patients (pre-tricuspid).
Pulmonary hypertension type 1 is idiopathic or secondary to connective tissue. Idiopathic PAH
affects mostly females. It is thought to be caused by an imbalance of vasodilator NO pathway and
vasoconstriction endothelin-1 pathway. It is characterised by increased pulmonary vascular resistance
due to remodelling and occlusion of the pulmonary arterioles.
Less commonly, RV failure could result from direct affection of myocardial disease by myocarditis,
cardiomyopathy, ischaemia, or arrhythmia. Right ventricular infarction complicates 30–50% of
inferior myocardial infarction and it is usually caused by occlusion of the proximal right coronary
artery. Compared with the left ventricle, the right ventricle is more resilient in the face of ischaemia.
This is due to less myocardial oxygen demand, coronary perfusion occurring throughout the cardiac
cycle, and a dual blood supply - the left anterior descending artery supplies the anterior two-thirds of
the septum. So, in the majority of cases, the RV recovers within a few days. However, during the
initial presentation profound hypotension and shock may be present.
The tricuspid valve is organically affected in rheumatic heart disease, in infective endocarditis in IV
drug addicts, or by trauma caused by pacemaker electrodes during implantation or retrieval. Ebstein’s
anomaly frequently presents as right heart failure in children or in early adulthood.
Gradual accumulation of fluid in the pericardial sac can compress the thin-walled RV and prevent its
filling, presenting as RHF. Constrictive pericarditis is one of these diagnoses which can be easily
missed. It is caused by fibrosis and calcification of the encasing pericardium, restricting diastolic
filling of the ventricles. The commonest cause used to be prior tuberculosis infection, but nowadays
it is mostly secondary to chest radiotherapy or previous cardiac surgery.

Clinical diagnosis

Symptoms of right heart failure are mainly due to systemic venous congestion and/or low cardiac
output. This includes exertional dyspnoea, fatigue, dizziness, ankle swelling, epigastric fullness and
right upper abdominal discomfort or pain.
In taking past medical history it is very important to inquire about the presence of coronary artery
disease, emphysema/chronic bronchitis, history of deep venous thrombosis, recurrent abortions,
autoimmune diseases – especially scleroderma and systemic lupus erythematosus (SLE) – and
infections, e.g. HIV, tuberculosis and schistosomiasis. Family history of PAH can be present as some
cases of PAH can have a familial occurrence.
Signs: raised jugular venous pulse (JVP), left parasternal lift, an accentuated second pulmonary
sound, right ventricular gallop, usually a pansystolic murmur over the tricuspid area which increases
with inspiration, and sometimes diastolic murmur of pulmonary insufficiency; also, an enlarged
tender liver, ascites frequently present as well as ankle oedema.
It is worth mentioning a few points to highlight the importance of raised JVP as a clinical sign. It is a
specific sign of right heart failure and reflects raised right atrial pressure. It correlates well with
raised left heart filling pressure in LV failure. Raised JVP is a prognostic marker. Analysis of the
SOLVD study has shown that it correlates with mortality and a risk of heart failure hospitalisation in
LVF. [6] Kussmaul's sign, which is an increase of JVP on inspiration, can help in pointing to the
cause of RHF. It is caused by impaired RV diastolic compliance with increased venous return, as
seen in constrictive pericarditis and RV infarction.
Right ventricular infarction should be suspected in the context of inferior MI by the triad of raised
JVP, hypotension and clear lung fields.

Technical clues to diagnosis

Manifest heart failure is not difficult to diagnose if careful attention is paid to clinical signs.
However, the underlying aetiology behind RHF can sometimes be elusive. On the one hand, if there
is a long history of ischaemic cardiomyopathy or chronic obstructive airway disease, usually history
plus simple investigations can easily determine the diagnosis. However, reaching the diagnoses of
other less common causes such as PAH, CTEPH or constrictive pericarditis can be a challenge.
Electrocardiography in patients with pulmonary hypertension shows signs of RV hypertrophy in the
form of right axis deviation, dominant R in V1 and dominant S in V5 or 6 + P pulmonale. An
elevated ST in V3R and V4R denoting RV infarction is present in 50% of inferior MI.
Echocardiography can give a rapid estimate of the RV size, shape and shift of the IVS. An RV/LV
basal diameter of more than 1 plus loss of sphericity of the LV (the D sign) are taken as evidence of a
rise in PAP. [7] Flattening of the septum occurs in diastole in volume overload: e.g. in the shunts and
in systole in pressure overload and in both systole and diastole as the pressure rises more as in all
advanced pulmonary hypertension, including Eisenmenger’s syndrome.
Because of the RV geometry and the complex 3D shape, measurement of RV function is a challenge.
Tricuspid annular plane systolic excursion (TAPSE) is a rapid and reproducible parameter as it is a
surrogate of the longitudinal fibres’ function. It measures the tucking effect of the apex on the
tricuspid annulus. It is not affected much by loading condition. It is angle-dependent. Longitudinal
displacement of 17 mm or less is indicative of poor RV function and poor prognosis. [8]
Estimation of pulmonary hypertension is an integral part of evaluation of a patient with suspected
RVF. PASP can be estimated non-invasively in the absence of pulmonary stenosis by measuring the
velocity of tricuspid regurgitation and applying the simplified Bernoulli equation and JVP. In
symptomatic patients, a peak tricuspid regurgitation velocity >2.8 m/s is consistent with the presence
of significant pulmonary hypertension.
Special attention should be paid to IVC diameter and distensibility in relation to respiration when
examined in the subcostal view. A distended IVC >21 mm with decreased inspiratory collapse points
to the presence of pulmonary hypertension and denotes raised right atrial pressure. [9]
Examination of the PA and the flow across it gives a further clue for PH. As RV pressure increases,
peak systolic velocity will occur earlier in systole, resulting in a more triangular shape of the
pulmonary flow envelope instead of the normal dome shape. Thus, a value of less than 100 ms of PA
acceleration time is regarded as indicative of PH. Also, a dilated PA >25 mm, especially if it is
associated with early diastolic pulmonary regurgitation >2.2 m/s, is another echocardiographic
feature.
In constrictive pericarditis, because of the dissociation of intrathoracic and intracardiac pressures,
there is a respiratory variation in the peak flow velocity across the mitral valve. Thus, there is a drop
of pressure in the pulmonary veins during inspiration but not in the left atrium, resulting in a decrease
of the normal gradient pressure responsible for LV filling. Consequently during inspiration, there is a
decrease in the initial E velocity on the transmitral flow velocity curve. During expiration, as the
intrathoracic pressure increases, the gradient of the pulmonary veins/left atrium is restored and is
seen on echo as a pronounced increase in the initial E velocity. In severe cases, a septal bounce can
be visualised.
Contrast echo is useful in the detection of intracardiac shunts.
A lung function test is needed when the diagnosis of cor pulmonale is contemplated to confirm the
presence and severity of obstructive airway disease. High-resolution CT of the chest is helpful when
underlying lung fibrosis is a possible diagnosis. Overnight oximetry is useful when sleep-breathing
disorders are suspected to demonstrate repeated episodes of desaturation from 10 to almost 40 sec
with an anoxia/hypoxia index (AHI) of at least 15/hour, consistent with the diagnosis.
Cardiac MRI is the gold standard nowadays for measurement of RV volumes and function. MRI has
the advantage of tissue characterisation which is useful in such conditions as arrythmogenic right
ventricular dysplasia or myocarditis. It is also useful in the diagnosis of congenital heart diseases.
Cardiac MRI, as well as CT, can detect pericardial thickening of more than 2 mm, which is useful
when constrictive pericarditis is considered.
CT pulmonary angiography is essential if CTEPH is suspected. Typical CT features in CTEPH
patients include: asymmetric enlargement of central pulmonary arteries in contrast to other causes of
pulmonary hypertension, plus a variation of size in segmental arteries and a mosaic pattern of lung
parenchyma (areas of hyperattenuation and low attenuation). [10]
Right heart catheterisation (RHC) is needed for the diagnosis of PAH and may also be needed in
constrictive pericarditis. PAH (pre-capillary) is defined by a high PAP above 25 mmHg with normal
wedge pressure <15 mmHg and increased pulmonary vascular resistance (>3 Wood units). In
constrictive pericarditis, there is an increase and equalisation of end pressure in all four chambers
plus a dynamic respiratory variation in LV and RV pressure tracings.

Biochemical markers
Systemic venous congestion affects the liver and kidney and results in derangement of their function.
Raised transaminases and bilirubin plus prolonged prothrombin time are common in right HF and
reflect poor prognosis. [11] Raised renal chemistry is frequently noted and may improve with
diuretics.
There are no specific biomarkers for right heart failure, but raised BNP and troponins reflect stress
and injury in different RHF scenarios. Their rise reflects the severity of the condition and portends
poor prognosis. For example, Krüger [12] has noted that BNP is elevated in acute pulmonary
embolism complicated by RV dysfunction, but is within normal range when RV function is
preserved. Patients with pulmonary embolism and plasma lactate level >2 mmol/L are at high risk of
death and adverse outcome. [13]

Diagnostic algorithm [4]

A useful working algorithm in right heart failure is to establish the presence of PH or another cause,
mainly primary myocardial disease or pericardial disease. If a careful history-taking – with a chest X-
ray to reveal symptoms and signs, and an ECG – raise suspicion of PH or RHF, then the next step is
to perform transthoracic echo. Echo is useful in investigating LV and RV systolic/diastolic function
and valvular structure and will confirm the presence of PH. At this stage, LVF as the commonest
cause can be proven or refuted. If PH is present and there is no significant LV dysfunction, then
proceed to exclude the second commonest – lung diseases. This includes lung function test, transfer
factor and high-resolution CT, and overnight oximetry if interstitial lung disease or OSA still needs
to be excluded. If tests are negative/inconclusive thus far, then a ventilation perfusion scan is the next
step for CTEPH exclusion. A positive V/Q scan necessitates CT pulmonary angiography for
confirmation, while a negative scan increases the probability of PAH type 1. RHC is needed in
addition to connective tissue disease screening, including antiphospholipid antibodies, HIV and a test
for schistosomiasis, if relevant.

Conclusion

Even though right ventricular failure does not take centre stage in the field of heart failure research
and clinical trials, it is actually the final pathway of left-sided heart failure. Pulmonary hypertension
is the commonest cause of right heart failure. Other causes are RV myocarditis, genetic
cardiomyopathy, ischaemia ,as well as pericardial disease. Due to the unusual anatomy of RV,
assessment of its function is a challenge. However, technical advances, especially in
echocardiography and cardiac MRI, are helping to evaluate RV function and volumes, as well as
measurement of pulmonary artery pressure. Careful history-taking, clinical examination and the
targeted use of investigations can elucidate the underlying pathology.

References

1. Voelkl N. F., Quaife R. A., Leinwand L. A., Barst R. J., McGoon M. D., Meldrum D. R., Dupuis J.,
Long C. S., Rubin L. J., Smart F. W., Suzuki Y. J., Gladwin M., Denholm E. M., & Gail D. B.
National Heart, Lung, and Blood Institute Working Group on Cellular and Molecular Mechanisms of
Right Heart Failure. Right ventricular function and failure. Report of the National Heart, Lung, and
Blood Institute working group on cellular and molecular mechanisms of right heart
failure. Circulation. 2006 Oct. 24 114 (17): 1883-91.
2. Mockel M., Searle J., Muller R., Slagman A., Storchmann H., Oestereich P., Wyrwich W., Ale-Abaei
A., Vollert J. O., Koch M., & Somasundaram R. Chief complaints in medical emergencies: do they
relate to underlying disease and outcome? The Charité Emergency Medicine Study (CHARITEM).
Eur J Emerg Med. 2013 April 20 (2): 103-8.
3. Hassanein M., Abdelhamid M., Ibrahim B., Elshazly A., Aboleineen M. W., Sobhy H., Nasr G.,
Elmesseiry F., Abdelmoniem A., Ashmawy M., Farag N., Youssef A., Elbahry A., Elrakshy Y., Sobhy
M., Abdel Dayem T. M., Ebeid H., Reda A., Boshra H., Saleh A., & Maggioni A. P. Clinical
characteristics and management of hospitalized and ambulatory patients with heart failure--results
from ESC heart failure long-term registry--Egyptian cohort. ESC Heart Failure. 2015 2: 159-67.
4. Galie N., Humbert M., Vachiery J. L., Gibbs S., Lang I., Torbicki A., Simonneau G., Peacock A.,
Vonk Noordegraaf A., Beghetti M., Ghofrani A., Gomez Sanchez M. A., Hansmann G., Klepetko W.,
Lancellotti P., Matucci M., McDonagh T., Pierard L. A., Trindade P. T., Zompatori M., Hoeper M.,
Aboyans V., Vaz Carneiro A., Achenbach S., Agewall S., Allanore Y., Asteggiano R., Paolo Badano
L., Albert Barberà J., Bouvaist H., Bueno H., Byrne R. A., Carerj S., Castro G., Erol Ç., Falk V.,
 Funck-Brentano C., Gorenflo M., Granton J., Iung B', Kiely D. G., Kirchhof P., Kjellstrom B.,
Landmesser U., Lekakis J., Lionis C., Lip G. Y., Orfanos S. E., Park M. H., Piepoli M. F., Ponikowski
P., Revel M. P., Rigau D., Rosenkranz S., Völler H., & Luis Zamorano J. 2015 ESC/ERS Guidelines
for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis
and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the
European Respiratory Society (ERS). Endorsed by the Association for European Paediatric and
Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation
(ISHLT). Eur Heart J. 2016 Jan. 37 (1): 67-119.
5. Kholdani C., Fares M., & Mohsenin V. Pulmonary hypertension in obstructive sleep apnea: is it
clinically significant? A critical analysis of the association and pathophysiology. Pulm Circ. 2015 June
5 (2): 220-7.
6. Dazner M. H., Rame E., Stevenson L. W., & Dries D. L. Prognostic importance of elevated jugular
venous pressure and a third heart sound in patients with heart failure. N Engl J Med. 2001 Aug. 23
345: 574-81.
7. Bleeker G. B., Steendijk P., Holman E. R., Yu C. M., Breithardt O. A., Kaandorp T. A., Schalij M. J.,
van der Wall E. E., Bax J. J., & Nihoyannopoulos P. Acquired right ventricular dysfunction. Heart.
2006 April 92 Suppl I: i14-8.
8. Forfia P. R., Fisher M. R., Mathai S. C., Housten-Harris T., Hemnes A. R., Borlaug B. A., Chamera
E., Corretti M. C., Champion H. C., Abraham T. P., Girgis R. E., & Hassoun P. M. Tricuspid annular
displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006 Nov 1
174 (9): 1034-41.
9. Kircher B. J., Himelman R. B., & Schiller N. B. Noninvasive estimation of right atrial pressure from
the inspiratory collapse of the inferior vena cava. Am J Cardiol. 1990 August 66: 493-6.
10. King M. A., Ysarel M., & Bergin C. J. Chronic thromboembolic pulmonary hypertension: CT
findings. AJR Am J Roentgenol. 1998 April 170 (4):955-60.
11. Ambrosy P. A., Gheorghiade M., Bubenek S., Vinereanu D., Vaduganathan M., Macarie C., &
Chioncel O. Romanian Acute Heart Failure Syndromes (RO-AHFS) study investigators. The
predictive value of transaminases at admission in patients hospitalized for heart failure: findings from
the RO-AHFS registry. Eur Heart J Acute Cardiovasc Care. 2013 June 2(2): 99-108.
12. Krüger S., Graf J., Merx M. W., Koch K. C., Kunz D., Hanrath P., & Janssens U. Brain natriuretic
peptide predicts right heart failure in patients with acute pulmonary embolism. Am Heart J. 2004 Jan.
14 7(1): 60-5.
13. Vanni S., Viviani G., Baioni M., Pepe G., Nazerian P., Socci F., Bartolucci M., Bartolini M., &
Grifoni S. Prognostic value of plasma lactate levels among patients with acute pulmonary embolism:
the thrombo-embolism lactate outcome study. Ann Emerg Med. 2013 March 6 1(3): 330-8.